Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
APTO has been the subject of several other reports. HC Wainwright set a $4.00 target price on Aptose Biosciences and gave the company a “buy” rating in a research note on Wednesday, November 15th. ValuEngine upgraded Aptose Biosciences from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 31st. Canaccord Genuity set a $7.00 target price on Aptose Biosciences and gave the company a “buy” rating in a research note on Wednesday, November 15th. Finally, Roth Capital restated a “buy” rating and set a $5.00 target price on shares of Aptose Biosciences in a research note on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.00.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. analysts predict that Aptose Biosciences will post -0.61 earnings per share for the current year.
An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC grew its holdings in shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the period. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 as of its most recent SEC filing. Institutional investors own 0.92% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.